Literature DB >> 18078390

Lessons from oncology to understand and treat pulmonary hypertension.

S Adnot1, S Eddahibi.   

Abstract

Pulmonary artery hypertension (PAH) is now considered to be a proliferative disorder characterised by unexplained proliferation of pulmonary artery smooth muscle cells (PA-SMCs) and pulmonary artery endothelial cells (PA-ECs). An abnormal phenotype of PA-SMCs and PA-ECs has been described in PAH and some analogies now appear between pulmonary vascular cells from patients with PAH and cancer cells. Such analogies are discussed here with respect to essential hallmarks of cancer cells and with the hope that new treatments targeted at one or more of these cancer cell abnormalities may be appropriate for PAH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18078390     DOI: 10.1111/j.1742-1241.2007.01618.x

Source DB:  PubMed          Journal:  Int J Clin Pract Suppl        ISSN: 1368-504X


  3 in total

Review 1.  Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.

Authors:  Johannes-Peter Stasch; Pál Pacher; Oleg V Evgenov
Journal:  Circulation       Date:  2011-05-24       Impact factor: 29.690

2.  A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.

Authors:  M Gomberg-Maitland; M L Maitland; R J Barst; L Sugeng; S Coslet; T J Perrino; L Bond; M E Lacouture; S L Archer; M J Ratain
Journal:  Clin Pharmacol Ther       Date:  2009-12-09       Impact factor: 6.875

3.  Inactivation of p53 Is Sufficient to Induce Development of Pulmonary Hypertension in Rats.

Authors:  S Jacquin; V Rincheval; B Mignotte; S Richard; M Humbert; O Mercier; A Londoño-Vallejo; E Fadel; S Eddahibi
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.